Stockscreener 앱 받기
4.07
3.33%
-0.14
시간 외 거래:
4.06
-0.01
-0.25%
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop - AD HOC NEWS
State Street (MYGN) reports 4.42M Myriad shares, 4.7% stake - Stock Titan
FirstGene Multiple Prenatal Screen launch drives engagement at ACOG2026, Myriad Genetics advances genetic care - Traders Union
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock - Insider Monkey
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics in record sell-off after Q1 miss - MSN
Myriad Genetics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) 2026-05-08 - Seeking Alpha
Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential - DirectorsTalk Interviews
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Myriad Genetics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Myriad Genetics Is Maintained at Hold by TD Cowen - Moomoo
Myriad Genetics to join two healthcare conferences in upcoming weeks - Traders Union
Myriad Genetics to join BofA meetings, Goldman webcast in June - Stock Titan
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - 富途牛牛
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Myriad Genetics Bets on Growth Amid Profit Squeeze - TipRanks
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns - Sahm
Myriad Genetics (MYGN) reports Q1 loss, misses revenue estimates - MSN
Myriad Genetics Q1 2026 earnings preview - MSN
Myriad Genetics Q1 2026 Financial Results: Revenue Breakdown, Net Loss, and Key Financial Statements - Minichart
Myriad Genetics Price Target Cut to $6.00/Share From $7.00 by TD Cowen - Moomoo
Myriad Genetics stock in sell-off after Q1 miss (MYGN:NASDAQ) - Seeking Alpha
Financial guidance for 2026 maintained as Myriad Genetics delivers first quarter results - Traders Union
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins - TradingView
Myriad Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
MYGN Financials: Income Statement, Balance Sheet & Cash Flow | Myriad Genetics - Stock Titan
Myriad Genetics (NASDAQ: MYGN) posts Q1 2026 loss amid higher costs and impairment - Stock Titan
Myriad Genetics Q1 2026 Earnings Call Transcript - MarketBeat
Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline By Investing.com - Investing.com South Africa
Myriad Genetics Q1 Earnings Call Highlights - Yahoo Finance
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS - ChartMill
Myriad Genetics Q1 2026 slides: cancer growth offsets prenatal decline - Investing.com
Earnings call transcript: Myriad Genetics Q1 2026 results show mixed performance - Investing.com India
Myriad: Q1 Earnings Snapshot - Barchart.com
Myriad Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Q1 2026 Myriad Genetics Inc Earnings Call Transcript - GuruFocus
MSN Money - MSN
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2% - Yahoo Finance
Myriad adds FDA-approved ovarian cancer test, launches new MRD assay - Stock Titan
Myriad Genetics (NASDAQ: MYGN) Q1 2026 revenue up 2% as loss widens - Stock Titan
Myriad Genetics (NASDAQ: MYGN) CCO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Myriad Genetics introduces FirstGene Multiple Prenatal Screen at ACOG2026 with interactive experience - Traders Union
RS Investment Management's Myriad Genetics Inc(MYGN) Holding History - GuruFocus
Myriad Genetics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Only 13% say first depression medication worked, Myriad survey finds - Stock Titan
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan - ChartMill
Myriad Genetics to unveil advanced decision-support tools in cancer care at ASCO26 - Traders Union
Analysts estimate Myriad Genetics (MYGN) to report a decline in earnings: What to look out for - MSN
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 - ChartMill
0.89%
0.56%
자본화:
|
볼륨(24시간):